Methylene blue-containing drugs for use in animals (21 CFR 500.27) (1978)

Government Record · U.S. Food and Drug Administration (regulation); Office of the Federal Register eCFR · March 10, 1978

U.S. Food et al., 1978-03-10: FDA regulation finding that orally administered methylene blue caused Heinz-body haemolytic anaemia, sometimes fatal, in cats, that its oral absorption is poor and erratic, and that oral methylene blue animal drugs are therefore new animal drugs – with prior "not a new drug" opinions revoked as of 10 April 1978.

The specific cause of the reaction was determined to be the methylene blue contained in the preparations. The reaction can be severe enough to cause death of treated animals.

21 CFR 500.27(a)(1)(i)

U.S. Food et al., 1978-03-10: FDA regulation finding that orally administered methylene blue caused Heinz-body haemolytic anaemia, sometimes fatal, in cats, that its oral absorption is poor and erratic, and that oral methylene blue animal drugs are therefore new animal drugs – with prior "not a new drug" opinions revoked as of 10 April 1978. C8 (product/quality of oral methylene blue preparations) and C9 (regulatory action). The CFR section also records the degradation chemistry relevant to quality: methylene blue is stepwise demethylated in alkaline solution to Azure B, Azure A and Azure C, and "the antiseptic efficacy of all of these excretion products is unsubstantiated". Record field (regulatory text), transcribed from the eCFR page; date is the operative date printed in the section. This predates the human supplement trade but is the FDA position on oral methylene blue – it is not an action against a named modern seller. Also filed as MTI-85 (claims C8). Study type: regulatory record.